Background Although survival outcomes of multiple myeloma (MM) have improved with the
development of new and effective agents, infection remains the major cause of morbidity …

Aim. To study infectious complications and factors attributable to them as reported in multiple
myeloma (MM) patients in the framework of state-of-the-art anticancer therapy. Materials & …

Introduction Treatment for multiple myeloma (MM) has continued to evolve with second
generation immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal …

Purpose This study sought to compare the efficacy of prophylactic long-acting and standard
granulocyte colony-stimulating factor (G-CSF) on febrile neutropenia, early infections, and …

Abstract Abstract 3017 Introduction: Multiple myeloma (MM) is a malignancy of clonal
plasma cells with resulting in an increase production of ineffective immunoglobulins with …

Bortezomib is effective in the therapy of multiple myeloma (MM), but causes infections that
are different from those associated with conventional chemotherapy. It is important to identify …

Objective To analyze the risk factors, distribution of pathogenic strains and tolerance of
pulmonary infection in patients with multiple myeloma (MM) during bortezomib …

Introduction Infection is a leading contributor to morbidity in heavily treated patients with
multiple myeloma (MM) with severe infection rates of up to 30% reported (Lim et. al. Clin …

Background Myeloma causes profound immunodeficiency and recurrent, serious infections.
Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of …

Background Patients with multiple myeloma (MM) remain at an increased risk of infection
due to the disease process, as well as the ensuing treatments. Methods We performed a …